hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang上一页:疾病新知:毛囊性白癜风
- 2022-05-02治疗的呕吐
- 2022-04-13试验性依那西普生物类似物 CHS-0214 3 期研究的主要终点
- 2022-04-12箕星宣布aficamten在中国获得突破性治疗药物认定
- 2022-04-11服用时应注意哪些功效和作用?
- 2022-04-07广西百色破获药案:涉及74家药店,3000多盒
- 2022-04-062013国际抗癫痫联合会抗癫痫药用指南
- 青年人牛皮癣危害三大危害要重视
- 腹式呼吸对牛皮癣患者的保健作用
- 男性牛皮癣的治疗方法牛皮癣的护理
- 牛皮癣通常会出现什么病因呢
- 牛皮癣直接影响体健康
- 牛皮癣的病因都有什么呢
- 牛皮癣的危害牛皮癣的发病特点
- 牛皮癣用什么药能治好4类药物不可少
- 牛皮癣有哪些症状特点了解牛皮癣的三个症状特点
- 牛皮癣患者饮食注意
- 牛皮癣患者要忌食什么呢
- 牛皮癣患者必懂牛皮癣用药大汇总
- 牛皮癣患者如何改善皮肤
- 牛皮癣患者勿食用过多菠菜牛皮癣患者注意正确穿衣
- 牛皮癣头皮脱屑原因简析及专用光疗仪治疗
- 牛皮癣发痒该用哪种药物呢
- 牛皮癣偏方治疗时需要注意什么
- 牛皮癣不能吃的东西
- 治疗牛皮癣好的方法是什么
- 母亲有牛皮癣会遗传给孩子吗
- 患有牛皮癣护理很重要3大护理重点要做好
- 当牛皮癣撞上你的亲戚
- 寻常型转变红皮病型牛皮癣的因素
- 如何有效避免牛皮癣复发
- 女性牛皮癣患者治疗时应该注意的事项
- 关于牛皮癣饮食保健
- 人群牛皮癣的发病特点
- 两种治疗牛皮癣的食物牛皮癣患者更容易得糖尿病
- 试验性依那西普生物类似物 CHS-0214 3 期研究的主要终点
- 箕星宣布aficamten在中国获得突破性治疗药物认定
- 服用时应注意哪些功效和作用?
- 广西百色破获药案:涉及74家药店,3000多盒
- 2013国际抗癫痫联合会抗癫痫药用指南
- 疾病新知:毛囊性白癜风
- JAHA:房颤患者炎症生物标志物和心力衰竭住院风险
- 癫痫猝死:凶手是谁?
- 心房颤动和扑动心电图诊断要点
- Clin Gastroenterology?H:?多潘立酮治疗对胃轻瘫症状的影响
- 癫痫患者手术评估新型工具
- JPD:左旋多巴-治疗帕金森病的卡比多巴肠凝胶与生活质量和症状有什么关系?